Posted on

FDA Approves Alzheimer’s Drug Leqembi , Slowed Cognitive Decline in Clinical Trial

90 1441307068

the staff of the Ridgewood blog

Washington DC,  the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease. The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease.

Continue reading FDA Approves Alzheimer’s Drug Leqembi , Slowed Cognitive Decline in Clinical Trial

Posted on

FDA Approves Aducanumab the first new treatment for Alzheimer’s disease in nearly 20 years

external content.duckduckgo 11

the staff of the Ridgewood blog

Ridgewood NJ, Aducanumab is the first new treatment for Alzheimer’s disease that has been approved for use in the US in nearly 20 years. It targets the underlying cause of the disease rather than its symptoms. While it is not a miracle drug, its approval will be a huge boost to dementia research. Alzheimer’s disease affects more than 30 million people around the world, most over the age of 65.

Continue reading FDA Approves Aducanumab the first new treatment for Alzheimer’s disease in nearly 20 years